rVSV ZEBOV埃博拉疫苗在几内亚一线工作人员中的安全性
在几内亚开展的开放标签、非随机免疫原性评价中,2016名接种rVSVΔG/ZEBOV-GP的一线工作人员与99名未接种对照纳入安全性队列。接种后3天内不良事件非常常见,超过70%的参与者报告至少一种不良事件;完成发热日记的887人中,15.22%报告接种后发热。随访期间共识别8例严重不良事件,其中2例与妊娠相关。
要点
- 接种后3天内不良事件非常常见,超过70%的参与者报告至少一种不良事件。
- 完成发热日记的887人中,接种后发热报告率为15.22%。
- 随访期间共识别8例严重不良事件,其中2例与妊娠相关。
核心结论
- 结果证实接种rVSV候选疫苗后3天内不良事件常见,在埃博拉持续传播背景下发热的发生尤其值得关注。
- 需要进一步研究以填补该疫苗在妊娠期及其他脆弱人群中使用的重要数据空白。
研究设计与样本
- 开放标签、非随机免疫原性评价,在几内亚科纳克里于2015年3月至2016年7月开展,接种一剂rVSVΔG/ZEBOV-GP。
- 拒绝接种的一线工作人员作为对照组;参与者随访3个月,部分亚组随访至接种后6个月。
- 安全性队列包括2016名接种参与者和99名对照。
主要发现
- 接种后3天访视时不良事件非常常见,超过70%的参与者报告至少一种不良事件。
- 最常报告的症状为头痛、乏力、关节痛、主观发热和肌痛。
- 完成发热日记的887人中,接种后发热报告率为15.22%。
- 与未接种组相比,接种组在接种后3天内发生的局部反应、乏力、头痛、关节痛、肌痛和主观发热具有统计学显著差异。
- 随访期间共识别8例严重不良事件,其中2例与妊娠相关。
临床怎么用
- 原文未提供临床使用建议。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: As part of the ring vaccination trial in Guinea, Front Line Workers were invited to participate in a sub-study to provide additional information on the immunogenicity and safety of rVSVΔG/ZEBOV-GP. Here we summarize the information on the safety follow-up. METHODS: An open-label, non-randomized, immunogenicity evaluation of one dose of rVSVΔG/ZEBOV-GP was conducted in Conakry, Guinea between March 2015 and July 2016. Front-line workers refusing vaccination were invited to participate as a control group. Participants were followed for 3 months with a subset followed-up for 6 months after vaccination. Women becoming pregnant during the follow-up were followed until pregnancy outcome. Solicited and unsolicited adverse events were monitored at each contact with participants using standardized study forms. RESULTS: 2016 vaccinated participants and 99 controls were included in the safety cohort. On the 3 days post-vaccination visit adverse events were very common, with over 70% of participants reporting at least one adverse event. The most frequently reported symptoms were headache, fatigue, arthralgia, subjective fever and myalgia. Among participants that completed fever diaries (n = 887), post-vaccination fever was reported by 15.22%. Comparing to the unvaccinated group, local reaction, fatigue, headache, arthralgia, myalgia and subjective fever occurring within the first 3 days post-vaccination were statistically significantly different in the vaccinated group compared to the unvaccinated. A total of 8 Serious Adverse Events were identified during follow-up. 2 SAEs were related to pregnancy. CONCLUSIONS: Results confirm that adverse events 3 days after vaccination with the rVSV candidate vaccine are common. The occurrence of fever is of particular concern in the context of ongoing Ebola transmission. Additional studies should address important data gaps regarding the use of the vaccine in pregnancy and other vulnerable populations.
引用
- Juan-Giner A, Tchaton M, Jemmy JP, et al. Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea. Vaccine. 2018. PMID: 30266489. doi:10.1016/j.vaccine.2018.09.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。